RespireRx Pharmaceuticals Inc (fka RSPI)

[DewDiligence]

>Pfizer has watched torcetrapib, asenapine, and indiplon turn from potentially replacing all of that loss, or more, to write-offs on its balance sheet.<

Let’s not forget Macugen for AMD. PFE paid EyeTech (now part of OSIP) more money in milestones than the drug sold during its entire time on the market.